Results 161 to 170 of about 21,287,561 (278)

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

open access: yesVeterinary and Comparative Oncology, EarlyView.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson   +5 more
wiley   +1 more source

VEGFR-1 inE. coliBBB infection

open access: yes, 2013
The key aspect of neonatal meningitis is related to the ability of pathogens to invade the blood-brain barrier (BBB) and to penetrate the central nervous system. In the present study we show that, in an in vitro model of BBB, on the basis of co-culturing primary bovine brain endothelial cells (BBEC) and primary bovine retinal pericytes (BRPC ...
Mario Alberghina   +7 more
openaire   +1 more source

Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines

open access: yesVeterinary and Comparative Oncology, EarlyView.
ABSTRACT Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high ...
Hiroki Sakuma   +6 more
wiley   +1 more source

VEGF inhibitor‐induced vascular dysfunction involves redox‐sensitive PARP activation and SIRT1 disruption

open access: yesExperimental Physiology, EarlyView.
Abstract Vascular endothelial growth factor receptor (VEGFR) inhibitors are effective antiangiogenic agents used in cancer therapy. However, they are associated with cardiovascular disease, including hypertension and vascular dysfunction. The molecular mechanisms underlying these cardiovascular toxicities are unclear, but oxidative stress might be ...
Karla B. Neves   +3 more
wiley   +1 more source

VEGF receptor 1 (FLT1; VEGFR-1) [PDF]

open access: yesScience-Business eXchange, 2012
openaire   +1 more source

The role of extracellular vesicles in cell–cell crosstalk in cardiotoxicity

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Administration of a pharmacological agent can result in off‐target cardiotoxicity which can be driven by cell–cell crosstalk between healthy and dysfunctional cardiac cells. Extracellular vesicles (EVs) are lipid bilayer structures that can move biological cargo between cells, facilitating cell–cell crosstalk.
Gabriella Bachynskyj‐Bilas   +5 more
wiley   +1 more source

VEGFR-1 [PDF]

open access: yes, 2019
openaire   +1 more source

VEGF receptor 1 (FLT1; VEGFR-1) [PDF]

open access: yesScience-Business eXchange, 2013
openaire   +1 more source

The role of the VEGF-C/VEGFR-3 axis in cancer progression

open access: yes, 2009
[[abstract]]Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR-3) (also called VEGFR-3) is activated by its specific ligand, VEGF-C, which promotes cancer progression.
Jen-Liang Su;C-J Yen;P-S Chen;S-E Chung;C-C Hong;I-H Kuo;H-Y Chen;Mien-Chie Hung;M-L Kuo   +1 more
core  

Quantitative Imaging of Pyruvate Metabolism in a Patient With Anaplastic Thyroid Cancer

open access: yesMagnetic Resonance in Medicine, Volume 96, Issue 2, Page 826-838, August 2026.
ABSTRACT Purpose Magnetic resonance imaging using hyperpolarized (HP) [1‐13C]‐pyruvate enables assessment of pyruvate metabolism in vivo and offers new insight into metabolic changes in response to cancer therapy. Widely used semi‐quantitative metrics of pyruvate metabolism can be affected by physiological factors that are extrinsic to intracellular ...
James A. Bankson   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy